Company Overview
Company Type: Public Company
Website: www.essapharma.com
Number of Employees: 50
Ticker: EPIX (NasdaqCM)
Year Founded: 2009


Business Description
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. The company develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. It has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
176.3
Total Enterprise Value
(33.0)
TEV/EBITDA
NM
EBIT
(44.1)
Cash & ST Invst.
209.5
P/Diluted EPS Before Extra
NM
Net Income
(37.7)
Total Debt
0.2
Price/Tang BV
0.9x
Total Assets
211.1
Total Debt/EBITDA
NM


Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023


Estimates Snapshot (Current Fiscal Year End: Sep-30-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS Normalized
(0.28)
(0.32)
(0.93)
(1.35)
(1.38)
Revenue (mm)
0.00
0.00
0.00
0.00
0.00

Forward Multiples (Current FY)

Price/Earnings
NM

Non-Periodic Estimates

Recommendation
Buy (1.33)
Target Price
24.94
Potential Upside
517.38%


Key Professionals
Name
Title
Parkinson, David Ross
President, CEO & Director
Wood, David S.
Chief Financial Officer
Virsik, Peter A.
Executive VP & COO
Cesano, Alessandra 
Chief Medical Officer & Executive VP
Barber, Nkengyal
Executive
Chandhasin, Chandtip
Executive
Harris, Loleta
Executive
Osbourne, Erica
Executive
Pondell, Steve
Executive
Rudsinski, Erin
Executive
Schuenemeyer, Terry
Executive
Thapar, Neil
Executive

Key Board Members
Name
Title
Glickman, Richard M.
Independent Chairman of the Board
Parkinson, David Ross
President, CEO & Director
Berger, Franklin M.
Independent Director
Requadt, Scott 
Independent Director
Sollis, Gary R.
Independent Director
Andersen, Raymond 
Scientific Advisor
Kantoff, Philip W.
Independent Director
Martin, John Alexander
Independent Director
Merendino, Lauren 
Director
Sadar, Marianne D.
Scientific Advisor
Thorell, Marella 
Independent Director
Zweifach, Sanford S.
Independent Director


Primary Industry Classification
Biotechnology


Primary Office Location
999 West Broadway Suite 720 | Vancouver, BC | V5Z 1K5 | Canada

Current and Pending Investors
AWM Investment Company Inc, Blackstone Life Sciences (Scott Requadt), BVF Partners L.P., Deerfield Management Company, L.P. Series C, Eventide Asset Management, LLC, Frazier Management, L.L.C. (James Brush), Mutual Fund Series Trust, Omega Fund Management Ltd, Omega Fund Management, LLC, OrbiMed Advisors LLC, Pfizer Inc. (NYSE:PFE), Soleus Capital Management, L.P.

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 4.04
Market Cap (mm)
178.1
Open
 3.85
Shares Out. (mm)
44.1
Previous Close
 4.04
Float %
59.0%
Change on Day
0.04
Shares Sold Short (mm)
0.0
Change % on Day
1.0%
Dividend Yield %
-
Day High/Low
 4.04/ 3.85
Diluted EPS Excl. Extra Items
(0.87)
52 wk High/Low
 7.09/ 1.92
P/Diluted EPS Before Extra
NM
Volume (mm)
0.02
Avg 3M Dly Vlm (mm)
0.03
Beta 5Y
2.09


 
Delayed Quote** | Last Updated on Oct-05-2023 12:00 AM (GMT-5)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Realm Therapeutics plc
Realm Therapeutics plc does not have significant operations. It intends to invest in, partner with, acquire, and/or be acquired by a company with development potential in the life sciences sector or other business prospects. Previously, it was engaged in developing therapies for the treatment of immune mediated diseases in adults and children. The company was formerly known as PuriCore plc and changed its name to Realm Therapeutics plc in December 2016. Realm Therapeutics plc was founded in 2016 and is headquartered in Malvern, Pennsylvania. As of July 31, 2019, Realm Therapeutics plc operates as a subsidiary of ESSA Pharma Inc.

United States and Canada
Pharmaceuticals
0.00
22.00
0.00
Essa Pharmaceuticals Corp.
Essa Pharmaceuticals Corp. is a research and consulting services company. It is based in Houston, Texas.

United States and Canada
Research and Consulting Services
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Sep-19-2023
-
Shelf Registration
Target
ESSA Pharma Inc. (NasdaqCM:EPIX)


200.00
Jul-08-2022
Jul-11-2022
Private Placement
Target
ESSA Pharma Inc. (NasdaqCM:EPIX)
BVF Partners L.P. Buyer Funds:Biotechnology Value Fund L.P., Biotechnology Value Trading Fund OS LP, Biotechnology Value Fund II, L.P., MSI BVF SPV, LLC

13.59
Oct-1-2021
-
Shelf Registration
Target
ESSA Pharma Inc. (NasdaqCM:EPIX)


58.74
Jun-21-2021
-
Shelf Registration
Target
ESSA Pharma Inc. (NasdaqCM:EPIX)


300.00
Feb-16-2021
Feb-17-2021
Public Offering
Target
ESSA Pharma Inc. (NasdaqCM:EPIX)


130.43
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-19-2023
Shelf Registration Filings
ESSA Pharma Inc. has filed a Shelf Registration in the amount of $200 million.
Sep-18-2023
Product-Related Announcements
ESSA Pharma Inc. Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Sep-18-2023
Changes in Company Bylaws/Rules
ESSA Pharma Inc. Amends Its Articles of Incorporation
Sep-18-2023
Index Constituent Drops
ESSA Pharma Inc.(NasdaqCM:EPIX) dropped from S&P Global BMI Index
Aug-23-2023
Shelf Registration Filings
ESSA Pharma Inc. has withdrawn its Shelf Registration dated June 21, 2021 in the amount of $300 million.

M&A Advisors
Blake, Cassels & Graydon LLP, Eversheds Sutherland, Oppenheimer & Co. Inc., Skadden, Arps, Slate, Meagher & Flom LLP


Advisors
Most Recent Auditor
Davidson & Company LLP
M&A Advisors
Blake, Cassels & Graydon LLP, Eversheds Sutherland, Oppenheimer & Co. Inc., Skadden, Arps, Slate, Meagher & Flom LLP
Private Placement Advisors
Bloom Burton & Co. Inc., Haywood Securities Inc., ROTH Capital Partners, LLC
Public Offering Advisors
Blake, Cassels & Graydon LLP, Davidson & Company LLP, Skadden, Arps, Slate, Meagher & Flom LLP


Most Recent Auditor
Davidson & Company


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

03:56 AM
EPIX
ESSA Pharma Inc 2023_10_05
Reports
14
The Economy Matters

Oct 02, 2023 02:34 AM
EPIX
The Economy Matters
Reports
8
CFRA Equity Research

Oct 01, 2023 12:24 PM
EPIX
ESSA Pharma Inc.
Reports
9
GlobalData

Sep 21, 2023 05:45 AM
EPIX
ESSA Pharma Inc (EPIX.NASD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
77
Oppenheimer & Co. Inc.
Gershell, Leland James
Sep 18, 2023 02:15 PM
EPIX
'7386 w/Xtandi Begins Randomized Phase 2; ESMO To Feature Phase 1 Data Update
Notes
6
Piper Sandler Companies
Catanzaro, Joseph Michael
Sep 18, 2023 06:12 AM
EPIX
Moving Forward With Full Dose Enza For Randomized Phase II
Notes
3
GlobalData

Sep 15, 2023 12:06 AM
EPIX
ESSA Pharma Inc (EPIX.NASD) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
61
MarketLine

Sep 14, 2023 06:01 AM
EPIX
ESSA Pharma Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
164
GlobalData

Sep 13, 2023 02:20 AM
EPIX
ESSA Pharma Inc (EPIX.NASD) - Financial Analysis Review
Reports
225
S&P Global Compustat

Sep 07, 2023 03:52 AM
EPIX
ESSA Pharma Inc 2023_09_07
Reports
14


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


BVF Partners L.P.

8,748,629

19.84

34.7

Jun-30-2023


Bellevue Asset Management AG

7,898,583

17.91

31.3

Jun-30-2023


PFM Health Sciences, LP

4,204,953

9.53

16.7

Jun-30-2023


Soleus Capital Management, L.P.

4,202,094

9.53

16.6

Jun-30-2023


Morgan Stanley, Investment Banking and Brokerage Investments

3,870,080

8.78

15.3

Jun-30-2023


Adage Capital Management, L.P.

1,042,531

2.36

4.1

Jun-30-2023


OrbiMed Advisors LLC

921,940

2.09

3.7

Jun-30-2023


Berger BA, C.F.A., MA, MBA, Franklin M.

684,404

1.55

2.7

Jan-10-2023


Rock Springs Capital Management LP

663,317

1.50

2.6

Jun-30-2023


Millennium Management LLC

469,002

1.06

1.9

Jun-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Morgan Stanley, Investment Banking and Brokerage Investments
3,870,080
764,872
Rock Springs Capital Management LP
663,317
138,373
Soleus Capital Management, L.P.
4,202,094
56,977
Millennium Management LLC
469,002
49,935
Susquehanna International Group, LLP, Asset Management Arm
49,530
49,530

Top Sellers
Sellers
Common Stock Equivalent Held
Change
OrbiMed Advisors LLC
921,940
(276,397)
Ally Bridge Group
0
(236,583)
Driehaus Capital Management LLC
28,300
(236,271)
Two Sigma Advisers, LP
82,300
(141,500)
Canadian Imperial Bank of Commerce, Asset Management Arm
160,643
(48,148)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
EPI-001 (Future), EPI-0011 (Future), EPI-002 (Future), EPI-506 (Future), EPI-7386 (Future)


Upcoming Events
Date/Time
Type
Dec-14-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Company Name
Source
Form Type
Size
Oct-03-2023
ESSA Pharma Inc. (NasdaqCM:EPIX)
SEC
S-3/A
447 KB
Sep-19-2023
ESSA Pharma Inc. (NasdaqCM:EPIX)
SEDAR
Shelf Prospectus (NI 44-102)
61 KB
Sep-19-2023
ESSA Pharma Inc. (NasdaqCM:EPIX)
SEDAR
Shelf Prospectus (NI 44-102)
134 KB
Sep-19-2023
ESSA Pharma Inc. (NasdaqCM:EPIX)
SEDAR
Shelf Prospectus (NI 44-102)
470 KB
Sep-19-2023
ESSA Pharma Inc. (NasdaqCM:EPIX)
SEC
S-3
547 KB
Sep-19-2023
ESSA Pharma Inc. (NasdaqCM:EPIX)
SEDAR
Shelf Prospectus (NI 44-102)
61 KB
Sep-19-2023
ESSA Pharma Inc. (NasdaqCM:EPIX)
SEDAR
Shelf Prospectus (NI 44-102)
10 KB
Sep-19-2023
ESSA Pharma Inc. (NasdaqCM:EPIX)
SEDAR
Shelf Prospectus (NI 44-102)
10 KB
Sep-19-2023
ESSA Pharma Inc. (NasdaqCM:EPIX)
SEDAR
Shelf Prospectus (NI 44-102)
10 KB
Sep-19-2023
ESSA Pharma Inc. (NasdaqCM:EPIX)
SEDAR
Shelf Prospectus (NI 44-102)
10 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Parkinson M.D., David Ross (President, CEO & Director)
Dec-30-2022
Common Shares
3,067
10,955
Private Acquisition
5.74
Form 4
Wood C.M.A., CPA, CMA, CPA, M.B.A., MBA, David S. (Chief Financial Officer)
Dec-30-2022
Common Shares
8,302
29,653
Private Acquisition
33.15
Form 4
Parkinson M.D., David Ross (President, CEO & Director)
Dec-22-2022
Common Shares
21,367
70,153
Open Market Acquisition
60.74
Form 4
Berger BA, C.F.A., MA, MBA, Franklin M. (Independent Director)
Dec-14-2022 - Dec-21-2022
Common Shares
(272,840)
(1,001,535)
Open Market Disposition
(28.50)
Form 4
-
Dec-14-2022
Common Shares
(25,000)
(103,031)
Open Market Disposition
-
Form 4
-
Dec-15-2022
Common Shares
(32,000)
(127,484)
Open Market Disposition
-
Form 4
-
Dec-15-2022
Common Shares
(50,000)
(196,446)
Open Market Disposition
-
Form 4
-
Dec-16-2022
Common Shares
(50,000)
(183,396)
Open Market Disposition
-
Form 4
-
Dec-20-2022
Common Shares
(43,617)
(151,595)
Open Market Disposition
-
Form 4
-
Dec-21-2022
Common Shares
(37,889)
(125,441)
Open Market Disposition
-
Form 4
-
Dec-21-2022
Common Shares
(34,334)
(114,143)
Open Market Disposition
-
Form 4
Bellevue Asset Management AG
Oct-26-2022 - Oct-27-2022
Common Shares
2,000,000
11,291,676
Open Market Acquisition
34.02
Form 4
-
Oct-26-2022
Common Shares
1,500,000
8,199,227
Open Market Acquisition
-
Form 4
-
Oct-27-2022
Common Shares
500,000
3,092,449
Open Market Acquisition
-
Form 4
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Glickman, Richard M.
Independent Chairman of the Board
-
-

Parkinson, David Ross
President, CEO & Director
(778) 331-0962
-

Berger, Franklin M.
Independent Director
-
-

Requadt, Scott 
Independent Director
(617) 949-2177
-
srequadt@clarusventures.com
Sollis, Gary R.
Independent Director
(604) 443-7130
(604) 683-5214
gary.sollis@dentons.com
Andersen, Raymond 
Scientific Advisor
-
-

Kantoff, Philip W.
Independent Director
-
-

Martin, John Alexander
Independent Director
-
-

Merendino, Lauren 
Director
-
-

Sadar, Marianne D.
Scientific Advisor
-
-

Thorell, Marella 
Independent Director
(212) 600-1902
-
mthorell@evelobio.com
Zweifach, Sanford S.
Independent Director
-
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Parkinson, David Ross
President, CEO & Director
(778) 331-0962
-

Wood, David S.
Chief Financial Officer
-
(604)7384080
dwood@essapharma.com
Virsik, Peter A.
Executive VP & COO
(778) 331-0962
-

Cesano, Alessandra 
Chief Medical Officer & Executive VP
-
-

Barber, Nkengyal
Executive
-
-
-
Chandhasin, Chandtip
Executive
-
-
-
Harris, Loleta
Executive
-
-
-
Osbourne, Erica
Executive
-
-
-
Pondell, Steve
Executive
-
-
-
Rudsinski, Erin
Executive
-
-
-
Schuenemeyer, Terry
Executive
-
-
-
Thapar, Neil
Executive
-
-
-
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
